JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Science Signaling

Volumn 9, Issue 421, 2016, Pages

  Gao, Sizhi P ^a   Chang, Qing ^a   Mao, Ninghui ^a   Daly, Laura A ^a   Vogel, Robert ^a   Chan, Tyler ^a   Liu, Shu Hui ^a   Bournazou, Eirini ^a   Schori, Erez ^a   Zhang, Haiying ^b   Brewer, Monica Red ^c   Pao, William ^c   Morris, Luc ^a   Ladanyi, Marc ^a   Arcila, Maria ^a   Manov Todorova, Katia ^a   De Stanchina, Elisa ^a   Norton, Larry ^a,d   Levine, Ross L ^a,d   Alta Bonnet, Gregoire ^a   Solit, David ^a,d   Zinda, Michael ^b   Huszar, Dennis ^e,f   Lyden, David ^a,b   Bromberg, Jacqueline F ^a,e   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d Department of Public Health   (United States)

^e ASTRAZENECA   (United Kingdom)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; JANUS KINASE 2; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING; WILD TYPE; XENOGRAFT; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DIET THERAPY; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JANUS KINASE 2; LUNG NEOPLASMS; MALE; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84962750039     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aac8460     Document Type: Article

References (58)

1. R. S. Herbst, J. V. Heymach, S. M. Lippman, Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
2. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, R. Palmero, R. Garcia-Gomez, C. Pallares, J. M. Sanchez, R. Porta, M. Cobo, P. Garrido, F. Longo, T. Moran, A. Insa, F. De Marinis, R. Corre, I. Bover, A. Illiano, E. Dansin, J. de Castro, M. Milella, N. Reguart, G. Altavilla, U. Jimenez, M. Provencio, M. A. Moreno, J. Terrasa, J. Muñoz-Langa, J. Valdivia, D. Isla, M. Domine, O. Molinier, J. Mazieres, N. Baize, R. Garcia-Campelo, G. Robinet, D. Rodriguez-Abreu, G. Lopez-Vivanco, V. Gebbia, L. Ferrera-Delgado, P. Bombaron, R. Bernabe, A. Bearz, A. Artal, E. Cortesi, C. Rolfo, M. Sanchez-Ronco, A. Drozdowskyj, C. Queralt, I. de Aguirre, J. L. Ramirez, J. J. Sanchez, M. A. Molina, M. Taron, L. Paz-Ares, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Onco. 13, 239-246 (2012).
3. T. S. Mok, Y.-L. Wu, S. Thongprasert, C.-H. Yang, D.-T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.-J. Yang, B. Chewaskulyong, H. Jiang, E. L. Duffield, C. L. Watkins, A. A. Armour, M. Fukuoka, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
4. G. R. Oxnard, M. E. Arcila, J. Chmielecki, M. Ladanyi, V. A. Miller, W. Pao, New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 17, 5530-5537 (2011).
5. H. A. Yu, M. E. Arcila, N. Rekhtman, C. S. Sima, M. F. Zakowski, W. Pao, M. G. Kris, V. A. Miller, M. Ladanyi, G. J. Riely, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 Patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240-2247 (2013).
6. R. Avraham, Y. Yarden, Feedback regulation of EGFR signalling: Decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12, 104-117 (2011).
7. L. Vecchione, B. Jacobs, N. Normanno, F. Ciardiello, S. Tejpar, EGFR-targeted therapy. Exp. Cell Res. 317, 2765-2771 (2011).
8. S. P. Gao, K. G. Mark, K. Leslie, W. Pao, N. Motoi, W. L. Gerald, W. D. Travis, W. Bornmann, D. Veach, B. Clarkson, J. F. Bromberg, Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007).
9. L. Song, B. Rawal, J. A. Nemeth, E. B. Haura, IL6/JAK1 pathway inhibition downregulates STAT3 and inhibits tumor growth in lung cancer. Mol. Cancer Ther. 10, 481-494 (2011).
10. Z. Yao, S. Fenoglio, D. C. Gao, M. Camiolo, B. Stiles, T. Lindsted, M. Schlederer, C. Johns, N. Altorki, V. Mittal, L. Kenner, R. Sordella, TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 107, 15535-15540 (2010).
11. H.-C. Chiu, D.-L. Chou, C.-T. Huang, W.-H. Lin, T.-W. Lien, K.-J. Yen, J. T.-A. Hsu, Suppression of Stat3 activity sensitizes Gefitinib-resistant non small cell lung cancer cells. Biochem. Pharmacol. 81, 1263-1270 (2011).
12. M. Hedvat, D. Huszar, A. Herrmann, J. M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C. M. Kowolik, H. Xin, B. Armstrong, G. Bebernitz, S. Weng, L. Wang, M. Ye, K. McEachern, H. Chen, D. Morosini, K. Bell, M. Alimzhanov, S. Ioannidis, P. McCoon, Z. A. Cao, H. Yu, R. Jove, M. Zinda, The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cel. 16, 487-497 (2009).
13. H. Xin, A. Herrmann, K. Reckamp, W. Zhang, S. Pal, M. Hedvat, C. Zhang, W. Liang, A. Scuto, S. Weng, D. Morosini, Z. A. Cao, M. Zinda, R. Figlin, D. Huszar, R. Jove, H. Yu, Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71, 6601-6610 (2011).
14. T. Murakami, N. Takigawa, T. Ninomiya, N. Ochi, M. Yasugi, Y. Honda, T. Kubo, E. Ichihara, K. Hotta, M. Tanimoto, K. Kiura, Effect of AZD1480 in an epidermal growth factor receptordriven lung cancer model. Lung Cance. 83, 30-36 (2014).
15. J.-H. Lee, K.-S. Park, A. T. Alberobello, B. Kallakury, M.-T. Weng, Y. Wang, G. Giaccone, The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clin. Cancer Res. 19, 6777-6786 (2013).
16. E. Dolgin, Companies hope for kinase inhibitor JAKpot. Nat. Rev. Drug Discov. 10, 717-718 (2011).
17. M. M. Seavey, P. Dobrzanski, The many faces of Janus kinase. Biochem. Pharmacol. 83, 1136-1145 (2012).
18. B. C. McFarland, J.-Y. Ma, C. P. Langford, G. Y. Gillespie, H. Yu, Y. Zheng, S. E. Nozell, D. Huszar, E. N. Benveniste, Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol. Cancer Ther. 10, 2384-2393 (2011).
19. J. S. Gheeya, Q.-R. Chen, C. D. Benjamin, A. T. Cheuk, P. Tsang, J.-Y. Chung, B. B. Metaferia, T. C. Badgett, P. Johansson, J. S. Wei, S. M. Hewitt, J. Khan, Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol. Ther. 8, 2386-2395 (2009).
20. R. B. Corcoran, G. Contino, V. Deshpande, A. Tzatsos, C. Conrad, C. H. Benes, D. E. Levy, J. Settleman, J. A. Engelman, N. Bardeesy, STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 71, 5020-5029 (2011).
21. G. J. Riely, W. Pao, D. Pham, A. R. Li, N. Rizvi, E. S. Venkatraman, M. F. Zakowski, M. G. Kris, M. Ladanyi, V. A. Miller, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839-844 (2006).
22. M. E. Arcila, G. R. Oxnard, K. Nafa, G. J. Riely, S. B. Solomon, M. F. Zakowski, M. G. Kris, W. Pao, V. A. Miller, M. Ladanyi, Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17, 1169-1180 (2011).
23. D. Harada, N. Takigawa, N. Ochi, T. Ninomiya, M. Yasugi, T. Kubo, H. Takeda, E. Ichihara, K. Ohashi, S. Takata, M. Tanimoto, K. Kiura, JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci. 103, 1795-1802 (2012).
24. S. B. Gendreau, R. Ventura, P. Keast, A. D. Laird, F. M. Yakes, W. Zhang, F. Bentzien, B. Cancilla, J. Lutman, F. Chu, L. Jackman, Y. Shi, P. Yu, J. Wang, D. T. Aftab, C. T. Jaeger, S. M. Meyer, A. De Costa, K. Engell, J. Chen, J.-F. Martini, A. H. Joly, Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin. Cancer Res. 13, 3713-3723 (2007).
25. A. Sawai, S. Chandarlapaty, H. Greulich, M. Gonen, Q. Ye, C. L. Arteaga, W. Sellers, N. Rosen, D. B. Solit, Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res. 68, 589-596 (2008).
26. W. Wang, Q. Li, T. Yamada, K. Matsumoto, I. Matsumoto, M. Oda, G. Watanabe, Y. Kayano, Y. Nishioka, S. Sone, S. Yano, Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 15, 6630-6638 (2009).
27. L. Regales, M. N. Balak, Y. Gong, K. Politi, A. Sawai, C. Le, J. A. Koutcher, D. B. Solit, N. Rosen, M. F. Zakowski, W. Pao, Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLOS On. 2, e810 (2007).
28. R. L. Levine, M. Wadleigh, J. Cools, B. L. Ebert, G. Wernig, B. J. P. Huntly, T. J. Boggon, I. Wlodarska, J. J. Clark, S. Moore, J. Adelsperger, S. Koo, J. C. Lee, S. Gabriel, T. Mercher, A. D'Andrea, S. Fröhling, K. Döhner, P. Marynen, P. Vandenberghe, R. A. Mesa, A. Tefferi, J. D. Griffin, M. J. Eck, W. R. Sellers, M. Meyerson, T. R. Golub, S. J. Lee, D. G. Gilliland, Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cel. 7, 387-397 (2005).
29. A. Sorkin, L. K. Goh, Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 315, 683-696 (2009).
30. E. Kario, M. D. Marmor, K. Adamsky, A. Citri, I. Amit, N. Amariglio, G. Rechavi, Y. Yarden, Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J. Biol. Chem. 280, 7038-7048 (2005).
31. S. E. Nicholson, D. Metcalf, N. S. Sprigg, R. Columbus, F. Walker, A. Silva, D. Cary, T. A. Willson, J.-G. Zhang, D. J. Hilton, W. S. Alexander, N. A. Nicola, Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc. Natl. Acad. Sci. U. S. A. 102, 2328-2333 (2005).
32. D. F. Calvisi, S. Ladu, A. Gorden, M. Farina, J.-S. Lee, E. A. Conner, I. Schroeder, V. M. Factor, S. S. Thorgeirsson, Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J. Clin. Invest. 117, 2713-2722 (2007).
33. E. M. Linossi, I. R. Chandrashekaran, T. B. Kolesnik, J. M. Murphy, A. I. Webb, T. A. Willson, L. Kedzierski, A. N. Bullock, J. J. Babon, R. S. Norton, N. A. Nicola, S. E. Nicholson, Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLOS On. 8, e70536 (2013).
34. N. J. Kershaw, J. M. Murphy, N. P. D. Liau, L. N. Varghese, A. Laktyushin, E. L. Whitlock, I. S. Lucet, N. A. Nicola, J. J. Babon, SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 20, 469-476 (2013).
35. S. Yang, K. Park, J. Turkson, C. L. Arteaga, Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Exp. Cell Res. 314, 413-419 (2008).
36. A. N. Bullock, M. C. Rodriguez, J. É. Debreczeni, Z. Songyang, S. Knapp, Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structur. 15, 1493-1504 (2007).
37. J. M. Sutherland, R. A. Keightley, B. Nixon, S. D. Roman, R. L. Robker, D. L. Russell, E. A. McLaughlin, Suppressor of cytokine signaling 4 (SOCS4): Moderator of ovarian primordial follicle activation. J. Cell. Physiol. 227, 1188-1198 (2012).
38. B. S. Hendriks, G. J. Griffiths, R. Benson, D. Kenyon, M. Lazzara, J. Swinton, S. Beck, M. Hickinson, J. M. Beusmans, D. Lauffenburger, D. de Graaf, Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. Syst. Biol. (Stevenage. 153, 457-466 (2006).
39. M. J. Lazzara, K. Lane, R. Chan, P. J. Jasper, M. B. Yaffe, P. K. Sorger, T. Jacks, B. G. Neel, D. A. Lauffenburger, Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptoractivating mutations. Cancer Res. 70, 3843-3850 (2010).
40. A. M. Walsh, M. J. Lazzara, Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells. J. Cell Sci. 126, 4339-4348 (2013).
41. M. Red Brewer, C.-H. Yun, D. Lai, M. A. Lemmon, M. J. Eck, W. Pao, Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 110, E3595-E3604 (2013).
42. W. Zhou, D. Ercan, L. Chen, C.-H. Yun, D. Li, M. Capelletti, A. B. Cortot, L. Chirieac, R. E. Iacob, R. Padera, J. R. Engen, K.-K. Wong, M. J. Eck, N. S. Gray, P. A. Jänne, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Natur. 462, 1070-1074 (2009).
43. J. Chmielecki, J. Foo, G. R. Oxnard, K. Hutchinson, K. Ohashi, R. Somwar, L. Wang, K. R. Amato, M. Arcila, M. L. Sos, N. D. Socci, A. Viale, E. de Stanchina, M. S. Ginsberg, R. K. Thomas, M. G. Kris, A. Inoue, M. Ladanyi, V. A. Miller, F. Michor, W. Pao, Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
44. S. Chandarlapaty, Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2, 311-319 (2012).
45. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, V. Serra, P. K. Majumder, J. Baselga, N. Rosen, AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cel. 19, 58-71 (2011).
46. V. Serra, M. Scaltriti, L. Prudkin, P. J. A. Eichhorn, Y. H. Ibrahim, S. Chandarlapaty, B. Markman, O. Rodriguez, M. Guzman, S. Rodriguez, M. Gili, M. Russillo, J. L. Parra, S. Singh, J. Arribas, N. Rosen, J. Baselga, PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogen. 30, 2547-2557 (2011).
47. R. B. Corcoran, H. Ebi, A. B. Turke, E. M. Coffee, M. Nishino, A. P. Cogdill, R. D. Brown, P. D. Pelle, D. Dias-Santagata, K. E. Hung, K. T. Flaherty, A. Piris, J. A. Wargo, J. Settleman, M. Mino-Kenudson, J. A. Engelman, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
48. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, D. Zecchin, R. L. Beijersbergen, A. Bardelli, R. Bernards, Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Natur. 483, 100-103 (2012).
49. R. Li, Z. Hu, S.-Y. Sun, Z. G. Chen, T. K. Owonikoko, G. L. Sica, S. S. Ramalingam, W. J. Curran, F. R. Khuri, X. Deng, Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol. Cancer Ther. 12, 2200-2212 (2013).
50. E. M. Linossi, J. J. Babon, D. J. Hilton, S. E. Nicholson, Suppression of cytokine signaling: The SOCS perspective. Cytokine Growth Factor Rev. 24, 241-248 (2013).
51. T. Yamashita, H. Kamada, S. Kanasaki, Y. Maeda, K. Nagano, Y. Abe, M. Inoue, Y. Yoshioka, Y. Tsutsumi, S. Katayama, M. Inoue, S. Tsunoda, Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis. Pharmazi. 68, 969-973 (2013).
52. B. Singh, R. J. Coffey, Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells. Annu. Rev. Physiol. 76, 275-300 (2014).
53. J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, J. Steinseifer, B. Molloy, E. Tokaji, H. Gardner, P. Phillips, M. Stumm, H. A. Lane, J. M. Dixon, W. Jonat, H. S. Rugo, Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27, 2630-2637 (2009).
54. A. Bosch, Z. Li, A. Bergamaschi, H. Ellis, E. Toska, A. Prat, J. J. Tao, D. E. Spratt, N. T. Viola-Villegas, P. Castel, G. Minuesa, N. Morse, J. Rodón, Y. Ibrahim, J. Cortes, J. Perez-Garcia, P. Galvan, J. Grueso, M. Guzman, J. A. Katzenellenbogen, M. Kharas, J. S. Lewis, M. Dickler, V. Serra, N. Rosen, S. Chandarlapaty, M. Scaltriti, J. Baselga, PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci. Trans. Med. 7, 283ra251 (2015).
55. G. Jerusalem, T. Bachelot, C. Barrios, P. Neven, A. Di Leo, W. Janni, R. de Boer, A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2-advanced breast cancer. Cancer Treat. Rev. 41, 94-104 (2015).
56. S. Yang, S. Qu, M. Perez-Tores, A. Sawai, N. Rosen, D. B. Solit, C. L. Arteaga, Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 66, 6990-6997 (2006).
57. I. Behrmann, T. Smyczek, P. C. Heinrich, H. Schmitz-Van de Leur, W. Komyod, B. Giese, G. Müller-Newen, S. Haan, C. Haan, Janus kinase (Jak) subcellular localization revisited: The exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak-receptor complex to be equivalent to a receptor tyrosine kinase. J. Biol. Chem. 279, 35486-35493 (2004).
58. T.-C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).